Elutia INC

Elutia Inc. announced third quarter 2026 results, highlighting progress in its NXT-41x drug delivery program with an upcoming FDA submission and robust growth in its cardiovascular business, while securing significant funding.

Elutia Inc. has completed the sale of its SimpliDerm business for up to $11 million, receiving $7.7 million at closing to fund its NXT-41x development.

Elutia Inc. received a notice from Nasdaq indicating its stock price has fallen below the minimum requirement for continued listing, triggering a compliance period.

Elutia Inc. has entered into a definitive agreement to sell its SimpliDerm business to Cellution Biologics Inc. for a total consideration of up to $11 million.

Elutia Inc. stockholders approved the expansion of its 2020 Incentive Award Plan and re-elected board members at the 2026 Annual Meeting.

Elutia Inc. announced it has regained full compliance with Nasdaq's minimum bid price and market value requirements, ensuring its continued listing.

Elutia Inc. filed its Q3 2026 Form 10-Q, detailing continued net losses and increased R&D expenses, alongside revenue growth and the impact of recent divestitures.

Elutia Inc. reports Q2 2026 results marked by continued net losses, a potential Nasdaq delisting, and significant litigation expenses, alongside progress in strategic divestitures and new financing.

Elutia Inc. reports a Q3 2025 net loss of $3.9 million, driven by a strategic divestiture of its CIED business, while facing Nasdaq delisting risk and focusing on its drug-eluting biomatrix platform.

Elutia Inc. reported a reduced net loss in Q2 2025, driven by a gain on warrant revaluation and EluPro sales growth, despite overall revenue decline and ongoing litigation costs.

Elutia Inc. reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while focusing on commercializing EluPro and managing legal liabilities.

Elutia Inc.'s third quarter 2024 results show a net income of $1.3 million, driven by a gain on revaluation of warrant liability, despite a slight decrease in net sales compared to the same period last year.

Elutia Inc. reported a net income of $53.38 million for 2025, driven by the strategic divestiture of its CIED business, while focusing on next-generation drug-eluting biomatrix products.

Elutia Inc.'s 2024 10-K filing reveals a year of strategic transition, marked by the sale of its Orthobiologics Business, FDA clearance for EluPro, ongoing litigation, and efforts to manage liquidity and future growth.

Elutia Inc.'s 2023 annual report highlights a strategic shift following the sale of its Orthobiologics business, focusing on device protection and women's health markets while navigating challenges from product recalls and litigation.

Kevin Rakin, a Director and 10% owner of Elutia Inc., received 176,000 shares of common stock on November 10, 2026.

Guido J Neels, a Director of Elutia Inc., received 117,000 shares of common stock on November 10, 2026.

David Colpman, a Director of Elutia Inc., received 117,000 shares of common stock on November 10, 2026.

Brigid Makes, a Director of Elutia Inc., received 117,000 shares of common stock on November 10, 2026.

Michelle Leroux Williams, CHIEF SCIENTIFIC OFFICER of Elutia Inc., received 446,000 shares of common stock on November 10, 2026.

Matthew Ferguson, CHIEF FINANCIAL OFFICER of Elutia Inc., received 446,000 shares of common stock on November 10, 2026.

Elutia Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and an amendment to its 2020 Incentive Award Plan.

Elutia Inc. will hold its Annual Meeting of Stockholders on May 29, 2025, to elect directors and ratify the appointment of PricewaterhouseCoopers LLP as the company's independent auditor.

Elutia Inc. will hold its 2025 annual meeting of stockholders on May 29, 2025, to elect directors and ratify the appointment of its independent registered public accounting firm.

Elutia Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 6, 2024, providing details on how stockholders can vote and access proxy materials.

Elutia Inc. will hold its annual stockholders meeting on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

HighCape entities distribute all Elutia Inc. Class A Common Stock to partners, shifting significant beneficial ownership.

A group of HighCape Capital entities and their managing members have significantly increased their beneficial ownership in Elutia Inc. to 26.4% following a $15 million equity and warrant purchase, indicating potential future strategic corporate actions.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.9% of Elutia Inc.'s Class A Common Stock as of June 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 2,192,980 shares, representing 4.9% of Elutia Inc.'s Class A Common Stock.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Elutia Inc.'s Class A Common Stock as of December 31, 2025.

Knollwood Investment Advisory, LLC has reported a 6.3% passive ownership stake in ELUTIA INC.'s Class A Common Stock.

AIGH Capital Management LLC and Orin Hirschman have reported a 7.6% beneficial ownership stake in Elutia Inc., holding 3,068,185 common shares.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a 9.99% beneficial ownership stake in Elutia Inc.'s Class A Common Stock as of March 31, 2025.